Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced Renal Cell Carcinoma (RCC). Axitinib prevents the progression of cancer by inhibiting angiogenesis and blocking tumor growth.
300+Total Product
85+Oncology Products
114+Countrywith our customers
20Anti Viral
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.
Axinix 1: Drug Registration Number: 341-324-010 Inclusion Date: 15-10-2017 Valid up to: 14-10-2022
Axinix 5: Drug Registration Number: 341-325-010 Inclusion Date: 10-10-2017 Valid up to: 14-10-2022
+880-2-57165371
+880-2-57165379
info@beaconmedicare.com.bd
